ArticleThe American journal of pathology1994
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
Article in The American journal of pathology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 149 citations in OpenAlex.
- Herbal Melanin Inhibits Colorectal Cancer Cell Motility, Invasiveness, and Epithelial-Mesenchymal Transition, Associated with u-PAR Downregulation Through JNK and ERK Pathways.Current issues in molecular biology · 2026Article
- Extracellular matrix in skin diseases: The road to new therapies.Journal of advanced research · 2023Review
- uPAR: An Essential Factor for Tumor Development.Journal of Cancer · 2021Review
- Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma.PloS one · 2019Article
- Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy.The journal of pathology. Clinical research · 2019Article
- Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.Journal of experimental & clinical cancer research : CR · 2017Article
- Characterization and function of human Ly-6/uPAR molecules.BMB reports · 2012Review
- Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.Cellular and molecular life sciences : CMLS · 2010Review
- Article
- Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells.Clinical & experimental metastasis · 2008Article
- uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells.The Journal of cell biology · 2007Article
- c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.Clinical & experimental metastasis · 2003Article
- Article
- High tPA-expression in primary melanoma of the limb correlates with good prognosis.British journal of cancer · 2000Article
- Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1.British journal of cancer · 2000Article
- Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas.British journal of cancer · 1999Article
- Article
- Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.British journal of cancer · 1998Article
- Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro.Clinical & experimental metastasis · 1998Article
- Assessment of the interaction between urokinase and reactive site mutants of protein C inhibitor.Journal of protein chemistry · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Degradation of the extracellular matrix and other tissue barriers by proteases like plasminogen activators (PAs) is a prerequisite for neoplastic growth and metastasis. Recently, we reported that highly metastatic behavior of human melanoma cells in nude mice correlates with urokinase-type PA (u-PA) expression and activity and with PA inhibitor type 1 and 2 (PAI-1, PAI-2) expression. Here we report on the occurrence of components of the PA system in the various stages of human melanoma tumor progression in situ. We studied the protein distribution on freshly frozen lesions of common nevocellular nevi (n = 25), dysplastic (= atypical) nevi (n = 16), early primary melanomas (n = 8), advanced primary melanomas (n = 11), and melanoma metastases (n = 17). Tissue-type PA was present in endothelial cells in all lesions, whereas in metastases it could be detected in tumor cells in a minority of the lesions. u-PA, its receptor, PAI-1, and PAI-2 could not be detected in benign and in early stages but appeared frequently in advanced primary melanoma and melanoma metastasis lesions. u-PA was detected in stromal cells and in tumor cells at the invasive front, the u-PA receptor and PAI-2 in tumor cells, and PAI-1 in the extracellular matrix surrounding tumor cells. Localization of the corresponding messenger RNAs and enzyme activities revealed a similar distribution. We conclude that plasminogen activation is a late event in melanoma tumor progression.
Indexed as
Identifiers
8291613PMC1887106W1732043081What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.